For governments & health authorities

A national plasma system, built from the ground up.

We help nations secure essential plasma therapies at home: a supply that serves patients, withstands global shocks, and returns value to the economy.

01 · The challenge

Essential therapies, supplied from somewhere else.

A small number of countries collect most of the world’s plasma. Nations that import their plasma-derived therapies are exposed whenever supply tightens: in a pandemic, a conflict, a natural disaster, or a swing in the market. Patients who depend on immunoglobulins, albumin, and clotting factors feel it first.

Building a national plasma system is not one project. It joins policy, donors, collection, quality, fractionation, and people, and each part only works if the others do. Most programs stall in the gaps between them.

02 · Our standard

Three outcomes, held together.

Health

Self-sufficiency

Domestic collection and a fractionation pathway that meet the population’s medical need.

Security

Resilience

A shield against disasters, conflict, pandemics, and market swings.

Economy

Net return

Jobs, skills, plasma revenue, and investment, reinvested in the health system.

03 · How we do it

Five phases, from policy to a working system.

Each phase is designed with the next in mind, so the program moves without stalls between ministries, operators, and manufacturers. How we build an operation, stage by stage ↗

Policy & framework

National plasma policy, regulatory framework, donor protection, and supply targets.

Donor program & collection network

Donor recruitment and care, center locations, capacity, and the operating model.

Quality system & regulatory pathway

A quality system built to FDA, EMA, MHRA, and MHLW/PMDA expectations, with national authority approval.

Fractionation pathway

Contract or toll fractionation first, with a route to domestic manufacturing where it makes sense.

Workforce & handover

Training, leadership, and governance, so the system runs and improves without us.

Global standards, local execution

FDAUnited StatesEMAEuropean UnionMHRAUnited KingdomMHLW / PMDAJapan

Across the Middle East, Africa, Latin America, and Southeast Asia, we design to the expectations of the world’s most demanding regulators so plasma can qualify for international fractionation. National authorities keep the final decision on licensing and approval.

04 · What you receive

A national program, ready to execute.

Strategy

National plasma strategy

Supply targets, policy options, and a phased roadmap to self-sufficiency.

Design

Program and infrastructure

The collection network, quality and regulatory framework, and fractionation pathway, designed together.

Case

The economic case

Patient supply, resilience, household income from donation, and domestic investment, set out for decision-makers.

A first conversation, in confidence.

We start with your country’s current supply, patient need, and policy goals, and outline what a national program could look like.

Discuss a National Program ↗